Cargando…

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson’s disease (LsPD) patients whose daily life depends primarily on caregivers and palliative care. Clinical metrics inadequately gauge efficacy in LsPD patients. We explored if a D(1/5) dopamine agonist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Mechelle M., Van Scoy, Lauren J., De Jesus, Sol, Hakun, Jonathan G., Eslinger, Paul J., Fernandez-Mendoza, Julio, Kong, Lan, Yang, Yang, Snyder, Bethany L., Loktionova, Natalia, Duvvuri, Sridhar, Gray, David L., Huang, Xuemei, Mailman, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216182/ https://www.ncbi.nlm.nih.gov/pubmed/37238699 http://dx.doi.org/10.3390/biom13050829

Ejemplares similares

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Dose-Dependent Regulation on Prefrontal Neuronal Working Memory by Dopamine D(1) Agonists: Evidence of Receptor Functional Selectivity-Related Mechanisms
por: Yang, Yang, et al.
Publicado: (2022)

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
por: Sohur, U. Shivraj, et al.
Publicado: (2018)

Serum Cholesterol and Nigrostriatal R2* Values in Parkinson's Disease
por: Du, Guangwei, et al.
Publicado: (2012)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson’s Risk
por: Zhang, Lijun, et al.
Publicado: (2017)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease
por: Jellen, Leslie C., et al.
Publicado: (2021)

Predicting the multi-domain progression of Parkinson’s disease: a Bayesian multivariate generalized linear mixed-effect model
por: Wang, Ming, et al.
Publicado: (2017)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease
por: Sterling, Nicholas W., et al.
Publicado: (2016)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
por: Riesenberg, Robert, et al.
Publicado: (2020)

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011)

No Dopamine Agonist Modulation of Brain [(18)F]FEOBV Binding in Parkinson’s Disease
por: Albin, Roger L., et al.
Publicado: (2022)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Welding fume exposure is associated with medial temporal lobe microstructural features resembling early Alzheimer disease
por: Lee, Eun-Young, et al.
Publicado: (2023)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

Compulsive Drumming Induced by Dopamine Agonists in Parkinson’s Disease: Another Aspect of Punding
por: Vitale, Carmine, et al.
Publicado: (2013)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
por: Mohammad, Mohammad Edrees, et al.
Publicado: (2021)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma
por: Prague, J K, et al.
Publicado: (2014)

Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation
por: Bandettini di Poggio, Monica, et al.
Publicado: (2013)

Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2014)

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
por: Jing, Xiao-Zhong, et al.
Publicado: (2023)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

Shape (but not volume) changes in the thalami in Parkinson disease
por: McKeown, Martin J, et al.
Publicado: (2008)

Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness
por: Crockett, Stacey L., et al.
Publicado: (2019)

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
por: Ecker, Daniel, et al.
Publicado: (2009)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
por: van der Vegt, Joyce P.M., et al.
Publicado: (2020)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8nc0tl7nd7b6sepb3gre0cnvt2